Ceftazidime–Avibactam Pharmacokinetic Comparative In Vivo/In Vitro Study in a Critically Ill Children Under High‐Volume Continuous Venovenous Hemodiafiltration

ABSTRACT Ceftazidime–avibactam is a novel cephalosporin/beta‐lactamase inhibitor combination developed to address increasing antimicrobial resistance. This report presents a comparative study of the pharmacokinetics of ceftazidime and avibactam, utilizing in vitro data derived from two experiments w...

Full description

Saved in:
Bibliographic Details
Main Authors: Michael Thy, Alexandre Debs, Gabrielle Lui, Leo Froelicher‐Bournaud, Jean‐Marc Tréluyer, Mehdi Oualha
Format: Article
Language:English
Published: Wiley 2025-08-01
Series:Pharmacology Research & Perspectives
Online Access:https://doi.org/10.1002/prp2.70139
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Ceftazidime–avibactam is a novel cephalosporin/beta‐lactamase inhibitor combination developed to address increasing antimicrobial resistance. This report presents a comparative study of the pharmacokinetics of ceftazidime and avibactam, utilizing in vitro data derived from two experiments with continuous venovenous hemodiafiltration (CVVHDF) simulation and a comparison with a previously published in vivo case report. The results highlight the importance of therapeutic drug monitoring and the need for higher dosing or continuous infusion of ceftazidime–avibactam in critically ill children under crontinuous renal replacement therapy (CRRT).
ISSN:2052-1707